0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Phase I Studies of Hypericin, the Active Compound in St. John's Wort, as an Antiretroviral Agent in HIV-Infected Adults: AIDS Clinical Trials Group Protocols 150 and 258

Roy M. Gulick, MD, MPH; Vincent McAuliffe, MD; Jeanne Holden-Wiltse, MPH; Clyde Crumpacker, MD; Leonard Liebes, PhD; Daniel S. Stein, MD; Patricia Meehan, PhD; Sheila Hussey, RN; Janet Forcht, RN; Fred T. Valentine, MD, for the AIDS Clinical Trials Group 150 and 258 Protocol Teams
[+] Article and Author Information

From New York University Medical Center, New York, New York; Harvard University School of Public Health and the AIDS Clinical Trial Unit, Beth Israel Hospital, Boston, Massachusetts; and National Institutes of Health, Rockville, Maryland.


Ann Intern Med. 1999;130(6):510-514. doi:10.7326/0003-4819-130-6-199903160-00015
Text Size: A A A

Background: Hypericin, the active compound in St. John's Wort, has antiretroviral activity in vitro. Many HIV-infected persons use St. John's wort.

Objective: To evaluate the safety and antiretroviral activity of hypericin in HIV-infected patients.

Design: Phase I study.

Setting: Four clinical research units.

Patients: 30 HIV-infected patients with CD4 counts less than 350 cells/mm3.

Intervention: Intravenous hypericin, 0.25 or 0.5 mg/kg of body weight twice weekly or 0.25 mg/kg three times weekly, or oral hypericin, 0.5 mg/kg daily.

Measurements: Safety was assessed at weekly visits. Antiretroviral activity was assessed by changes in HIV p24 antigen level, HIV titer, HIV RNA copies, and CD4 cell counts.

Results: Of the 30 patients who were enrolled, 16 discontinued treatment early because of toxic effects. Severe cutaneous phototoxicity was observed in 11 of 23 (48% [95% CI, 27% to 69%]) evaluable patients, and dose escalation could not be completed. Virologic markers and CD4 cell count did not significantly change.

Conclusions: Hypericin caused significant phototoxicity and had no antiretroviral activity in the limited number of patients studied.

Figures

Grahic Jump Location
Figure.
Disposition of the study patients.

*To establish the pharmacokinetics of oral hypericin, a single oral dose of hypericin (1.25 mg/kg) was tested in four patients in the cohort that received 0.25 mg/kg of intravenous hypericin twice weekly.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)